DNA player Touchlight doubles fundraising this year with latest round of private backers on board
When the news got out about Touchlight’s $60 million financing round in March, the most promising part of it all was the suggestion that the company could triple the production of its “doggybone” DNA and supply up to 1 billion Covid-19 shot doses per month.
Now, the company will have more than double that amount of money to work with.
The UK-based biotech that makes enzymatic DNA announced the extension of its fundraising round to a total of $125 million, the company announced. This comes at a time when demand for synthetic DNA has grown in the last year. Touchlight says the funding will help it become the largest synthetic DNA manufacturer in the world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.